Results 131 to 140 of about 47,200 (309)
Dabigatran for catastrophic antiphospholipid syndrome
Blood Coagulation & Fibrinolysis, 2019 : Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight ...
Marc Sorigue +6 more
openaire +5 more sources
Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays
International Journal of Laboratory Hematology, EarlyView.
Agathe Herb +3 more
wiley +1 more source
Bioactives From Brown Algae: Antioxidant, Anti‐Inflammatory, Anticancer, and Antimicrobial Potential
ChemBioEng Reviews, Volume 12, Issue 3, June 2025.This review explores key bioactives in brown algae and their antioxidant, anti‐inflammatory, anticancer, and antimicrobial properties. Covering studies from 2014 to 2024, it highlights their relevance in pharmaceuticals, nutraceuticals, cosmetics, and foods, while addressing challenges and future directions to unlock their full potential.
Irvin Fonseca‐Barahona +2 more
wiley +1 more source
Dabigatran for left ventricular thrombus
Indian Heart Journal, 2015 Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued
Satyavan Sharma +2 more
openaire +3 more sources
Clinical Cardiology, Volume 48, Issue 6, June 2025.A retrospective, observational, claims‐based cohort study identified that over 24‐months follow‐up of patients recently diagnosed with AF, a strategy of first‐line dronedarone was associated with similar or lower rates of any outpatient or inpatient visits, and lower total payer costs compared with an ablation‐based approach. ABSTRACT Background Rhythm
Stephen J. Greene +9 more
wiley +1 more source
JA Clinical ReportsBackground It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada +4 more
doaj +1 more source
Therapeutic Advances in Neurological Disorders, 2015 Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris +3 more
doaj +1 more source
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
Pharmaceuticals, 2012 Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients.
Josef Finsterer, Claudia Stöllberger
doaj +1 more source
Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]
, 2016 A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE +3 more
core +1 more source
The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study [PDF]
, 2015 The efficacy and safety of the new oral anticoagulants (NOAC) and the benefits of extended duration thromboprophylaxis following hip and knee replacements remain uncertain.
Aylin, P +4 more
core +2 more sources